# **Demo: Comparing vaccination strategies with** finalsize

This is a fictional use case to demonstrate: The kind of new insights Epiverse tools are unlocking • • possible







- Why these tools need to be open-source and disseminated are widely as



## **Fictional situation**

Outbreak currently ongoing in Senegal 1,000,000 doses of vaccines (80% efficacy) available

How to distribute a limited doses supply?



•

•





indirect protection from immunized individuals



# In a partially immunized population, unimmunized individuals get



A

#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals

D

B







Α

#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals

B







#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals









#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals









#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals







A

#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals

B







#### In a partially immunized population, unimmunized individuals get indirect protection from immunized individuals

B



A





#### **3** scenarios to compare

population via herd immunity?

Scenario A: Give 1,000,000 doses to the youngest age group **Scenario B**: Give 1,000,000 doses to the oldest age group



•

•

•

How to distribute the 1,000,000 doses to maximize their impact in the entire

- Scenario C: Give 1,000,000 doses uniformly across the whole population





lleing finaleizo	demo_grp
USING MAISIZE	00_05
	05_10
library(finalsize)	10_15
	15_20
	20_25
	25_30
	30_35
	35_40
final_size(	40_45
	45_50
r0 = r0,	50_55
	55_60
contact_matrix,	60_65
	65_70
demography_vector,	70_75
suscentibility	75_80
p_susceptibility	00_05
	05_10
	10_15
	15_20

#### data.org

susc_grp	susceptibility	p_infected
susc_grp_1	0.70	0.0431598
susc_grp_1	0.70	0.0707364
susc_grp_1	0.70	0.0835088
susc_grp_1	0.70	0.0723355
susc_grp_1	0.70	0.0495588
susc_grp_1	0.70	0.0526637
susc_grp_1	0.70	0.0541672
susc_grp_1	0.70	0.0581954
susc_grp_1	0.70	0.0603913
susc_grp_1	0.70	0.0557931
susc_grp_1	0.70	0.0603806
susc_grp_1	0.70	0.0540232
susc_grp_1	0.70	0.0569088
susc_grp_1	0.70	0.0597207
susc_grp_1	0.70	0.0632707
susc_grp_1	0.70	0.0483331
susc_grp_2	0.14	0.0087850
susc_grp_2	0.14	0.0145655
susc_grp_2	0.14	0.0172894
susc_grp_2	0.14	0.0149048

#### Outcome







#### Number of infected by age group and scenario





Vaccinating across all age groups • reduces most the overall number of infections





#### Outcome

Vaccinating across all age groups • reduces most the overall number of infections

Vaccinating across all age groups • protects more the youngest age group than targeted campaigns





#### Number of infected by age group and scenario



#### **Potential improvements**

Flexibility is baked into the tool and virtually any improvement is possible:

Take into account age-specific fatality rate
Take into account different contact rates across different regions
Multiple doses vaccine schema
etc.



\_



•

•

- Vaccinating across all age groups reduces most the overall number of infections
- Vaccinating across all age groups protects more the youngest age group than targeted campaigns





•

•

Vaccinating across all age groups reduces most the overall number of infections

Vaccinating across all age groups protects more the youngest age group than targeted campaigns

For the Senegal case and this specific outbreak!



#### Localism

Insights from Africa may not fit Latin America or Europe since results depends on the population pyramid and contact patterns.

It is important the everyone has access to these tools & capacity to run analyses and simulations in their own context.

